MRKR Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.80%

Insider Buying (Last 12 Months): $1,809,072.00

Insider Selling (Last 12 Months): $0.00

Marker Therapeutics Insider Trading History Chart

Marker Therapeutics Share Price & Price History

^$1.42

▲ +0.15 (11.81%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Marker Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/23/2024	Enterprise Associates 16 New	Major Shareholder	Buy	554,250	$3.20	$1,773,600.00	1,625,678
12/23/2024	Steve Elms	Director	Buy	11,085	$3.20	$35,472.00	325,370
3/16/2023	Norman David Eansor	Director	Buy	14,285	$17.50	$249,987.50	16,713

SEC Filings (Institutional Ownership Changes) for Marker Therapeutics (NASDAQ:MRKR)

22.39% of Marker Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Marker Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/14/2025	Virtu Financial LLC	28,329	$25K	0.0%	N/A	0.219%
11/14/2025	Two Sigma Investments LP	36,540	$33K	0.0%	N/A	0.282%
8/14/2025	Jane Street Group LLC	21,800	$33K	0.0%	N/A	0.193%
5/16/2025	Alyeska Investment Group L.P.	261,777	$0.32M	0.0%	-71.4%	2.314%
2/17/2025	NEA Management Company LLC	1,625,678	$5.06M	0.3%	+51.7%	15.179%
2/17/2025	Millennium Management LLC	16,108	$50K	0.0%	N/A	0.150%
2/17/2025	Alyeska Investment Group L.P.	915,591	$2.85M	0.0%	N/A	8.549%
2/14/2025	Northern Trust Corp	54,156	$0.17M	0.0%	+66.9%	0.506%
2/14/2025	Blue Owl Capital Holdings LP	554,250	$1.72M	0.4%	N/A	5.175%
2/12/2025	Aisling Capital Management LP	325,370	$1.01M	0.4%	+3.5%	3.038%
2/11/2025	LPL Financial LLC	79,730	$0.25M	0.0%	N/A	0.744%
11/19/2024	Invst LLC	20,000	$56K	0.0%	N/A	0.224%
8/7/2024	Wedbush Securities Inc.	69,500	$0.38M	0.0%	+52.7%	0.779%
1/24/2024	International Assets Investment Management LLC	11,000	$60K	0.0%	+1,000.0%	0.124%
10/12/2023	Matrix Asset Advisors Inc. NY	15,000	$68K	0.0%	-62.5%	0.170%
7/27/2023	Virtu Financial LLC	20,472	$63K	0.0%	N/A	0.233%
7/18/2023	Matrix Asset Advisors Inc. NY	40,000	$0.12M	0.0%	+60.0%	0.455%
5/17/2023	Long Focus Capital Management LLC	146,100	$0.10M	0.0%	-90.0%	1.660%
5/12/2023	Long Focus Capital Management LLC	68,400	$49K	0.0%	-95.3%	0.777%
5/9/2023	Aisling Capital Management LP	314,286	$0.22M	0.1%	-90.0%	3.571%
5/9/2023	AR Asset Management Inc.	40,700	$29K	0.0%	N/A	0.463%
1/19/2023	Matrix Asset Advisors Inc. NY	250,000	$68K	0.0%	-37.5%	0.299%
11/15/2022	Long Focus Capital Management LLC	1,461,000	$0.54M	0.1%	-40.0%	1.748%
10/25/2022	Raymond James & Associates	94,000	$35K	0.0%	N/A	0.112%
10/24/2022	Matrix Asset Advisors Inc. NY	400,000	$0.15M	0.0%	+60.0%	0.478%
7/15/2022	Matrix Asset Advisors Inc. NY	250,000	$83K	0.0%	+66.7%	0.299%
5/10/2022	AR Asset Management Inc.	279,000	$0.12M	0.0%	+290.2%	0.336%
4/19/2022	Wedbush Securities Inc.	90,068	$40K	0.0%	+44.0%	0.108%
2/15/2022	Kennedy Capital Management Inc.	590,118	$0.56M	0.0%	-3.5%	0.710%
2/14/2022	Long Focus Capital Management LLC	1,233,257	$1.17M	0.2%	N/A	1.484%
2/10/2022	Matrix Asset Advisors Inc. NY	150,000	$0.14M	0.0%	N/A	0.181%
2/10/2022	Acadian Asset Management LLC	39,507	$37K	0.0%	N/A	0.048%
2/7/2022	Victory Capital Management Inc.	621,670	$0.59M	0.0%	-31.4%	0.748%
2/7/2022	AR Asset Management Inc.	71,500	$68K	0.0%	-74.4%	0.086%
2/3/2022	ACT Capital Management LLC	354,400	$0.34M	0.2%	-19.3%	0.427%
11/16/2021	ACT Capital L.L.C.	439,400	$0.74M	0.4%	+4.6%	0.529%
11/16/2021	Two Sigma Advisers LP	878,300	$1.48M	0.0%	-35.2%	1.057%
11/16/2021	Two Sigma Investments LP	887,009	$1.50M	0.0%	-11.3%	1.068%
11/15/2021	Marshall Wace LLP	170,712	$0.29M	0.0%	-47.9%	0.205%
11/12/2021	Renaissance Technologies LLC	985,100	$1.67M	0.0%	+146.3%	1.186%
11/8/2021	Mandatum Life Insurance Co Ltd	99,000	$0.17M	0.0%	N/A	0.119%
11/5/2021	Advisor Group Holdings Inc.	44,713	$76K	0.0%	-13.4%	0.054%
11/2/2021	Victory Capital Management Inc.	906,770	$1.53M	0.0%	-1.8%	1.091%
9/3/2021	Parametric Portfolio Associates LLC	75,068	$0.21M	0.0%	-17.2%	0.090%
8/16/2021	State Street Corp	192,751	$0.54M	0.0%	-66.5%	0.232%
8/16/2021	Goldman Sachs Group Inc.	136,241	$0.38M	0.0%	+442.8%	0.164%

Data available starting January 2016

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Today's Range

Now: $1.42

$1.27

$1.43

50 Day Range

MA: $1.03

$0.86

$1.42

52 Week Range

Now: $1.42

$0.81

$5.95

Volume

501,557 shs

Average Volume

267,162 shs

Market Capitalization

$23.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.35

Who are the company insiders with the largest holdings of Marker Therapeutics?: Marker Therapeutics' top insider shareholders include:
Enterprise Associates 16 New (Major Shareholder)
Steve Elms (Director)
Learn More about top insider investors at Marker Therapeutics.
Who are the major institutional investors of Marker Therapeutics?: Marker Therapeutics' top institutional investors include:
Two Sigma Investments LP — 0.28%
Virtu Financial LLC — 0.22%
Learn More about top institutional investors of Marker Therapeutics stock.
Which major investors are buying Marker Therapeutics stock?: Within the last quarter, MRKR stock was acquired by institutional investors including:
Two Sigma Investments LP
Virtu Financial LLC
In the last year, these company insiders have bought Marker Therapeutics stock:
Enterprise Associates 16 New (Major Shareholder)
Steve Elms (Director)
Learn More investors buying Marker Therapeutics stock.